Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has today published on its website its Annual Report and Accounts for the financial year ended 30 June 2021, together with its Notice of Annual General Meeting (“AGM”). Shareholders will be sent either printed copies of these materials or a letter notifying them that they are available on the Company’s website, depending on the preferences they have expressed to the Company’s registrar.
As announced on 30 September 2021, the Company’s AGM will be held at 10.00 a.m. on 23 November 2021, at the Company’s registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA. The Company intends to hold a physical AGM this year however it is closely monitoring the COVID-19 situation, including UK Government and ICSA guidance and will continue to do so in the lead up to the AGM. The health of our shareholders, employees and stakeholders remains extremely important to us and accordingly, should guidance change in the run up to the Company’s intended AGM date, the Company may make the decision to hold a closed AGM where shareholders, advisors and other guests will not be allowed to attend in person. In the event that any changes to the 2021 AGM become unavoidable, we will announce them on the Company’s website at www.physiomics.co.uk.
A copy of the Notice of AGM, containing further details of the resolutions, as well as a copy of the Company’s Annual Report and Accounts will be made available today on the Company’s website at www.physiomics.co.uk/investors/reports-prospectus/.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.
For more information please visit: